Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

BACKGROUND

Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial.

METHODS

EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110.

FINDINGS

Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001).

INTERPRETATION

Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor.

FUNDING

Boehringer Ingelheim and Eli Lilly.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

BACKGROUND

The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.

METHODS

EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110.

FINDINGS

Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1).

INTERPRETATION

In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease.

FUNDING

Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.

Infection Prevention, Operational Workflows, and Implementation Checklists for Whole-Lung Low-Dose Radiation Therapy (LD-RT) for COVID-19-Related Pneumonia

Purpose/Objective(s)

Low-Dose Radiation Therapy (LD-RT) is an emerging treatment option for patients with COVID-19 related pneumonia. Infectivity of the SARS-CoV-2 virus complicates incorporation of LD-RT into existing radiation oncology clinics.

Materials/Methods

The first phase I/II trial of LD-RT for COVID-19-related pneumonia implemented novel operational protocols to address risk of infection and respiratory events. Patients were transported from hospital rooms to linear accelerators and treated with 0.5 Gy or 1.5 Gy using pre-planned, two-dimensional treatments prepared using diagnostic x-rays and caliper measurements. Workflows were revised over time to balance infection risks with implementation burden.

Results

Between April 24 and December 7, 2020, fifty-two patients were enrolled and forty were treated. The end-to-end process comprised 16 distinct teams and > 120 cooperating staff members (> 50 core radiation oncology staff). The trial was operationalized at two hospitals at the onset of the COVID-19 pandemic, prior to vaccine availability. Teams included trial leadership/screening (n > 4), inpatient floor staff (n > 10), clinical trials staff and coordinators (n = 8), transport (n = 2), radiation therapists (n > 20), respiratory therapists (n = 5), radiation nursing (n > 7), ICU nursing (n = 4), rapid response teams (n = 4), medical physics (n > 4), dosimetry (n > 3), infection prevention (n > 3), environmental services (n > 6), security (n = 7), lab personnel (n = 1), and physicians from radiation oncology (n = 7), infectious diseases (n = 2), pulmonary/critical care medicine (n = 2), anesthesia (n = 2), and internal medicine (n > 20) [total > 120]. All non-intubated patients were transported by a multi-disciplinary team, consisting of a physician, nurse, transporter, infection prevention specialist, and (when needed) a respiratory therapist. Treatments occurred after normal clinic hours, were initiated by team huddles, check lists, and included personal protective equipment supervision at multiple time points. Transport routes were 880 to 1760 feet (0.33 miles) one-way, with 1 to 3 elevator banks and required 20-35 minutes for round-trip transport and treatment. Oxygen supplementation in non-intubated patients ranged from 2 to 15 L/min. One intubated patient was transported with a portable ventilator and accompanying ICU staff. There were no code-level events during transport. No patient-facing staff contracted COVID-19 from trial activities. Workflow burden was successfully reduced and protocols relaxed over time with increased staff experience.

Conclusion

Whole-lung low-dose radiation therapy (LD-RT) for COVID-19-related pneumonia was successfully incorporated into existing workflows at a major academic university. Forty patients were treated with no code-level events, and no staff contracted the virus during eight months of trial accrual. Instructional materials and implementation check lists are provided.

[Severe Eyeball and Facial Skeletal Injuries Caused by Firefighting Sport]

The aim of this work is to draw attention to possible injuries of the eye and the facial skeleton caused by firefighting sport. There was a group of 9 patients presented who were treated from 2006 to 2015 in the Department of Ophthalmology at the University Hospital in Pilsen and diagnosed with severe eyeball contusion after being hit by a jet of water and/or a water pipe. Three cases are presented in detail.

[Sebaceous gland tumor with a rare gene mutation within a tumor syndrome: Muir-Torre syndrome]

Muir-Torre syndrome is a rare autosomal dominant subtype of hereditary nonpolyposis colorectal carcinoma and is characterized by the simultaneous occurrence of sebaceous gland neoplasms with visceral and urogenital malignancies. This article describes the case of a 72-year-old patient who was referred to our clinic for removal of an upper eyelid tumor, showing the course from the clinical findings to the rare diagnosis of Muir-Torre syndrome.

ARDS in an HIV-positive patient associated to respiratory syncytial virus

We describe a clinical case of ARDS in an HIV infected patient. ARDS was associated to a respiratory syncytial virus infection that triggered a suspected Pneumocystis infection that despite missing etiologic proofs was treated with antimycotics. As rather limited information on RSV associated ARDS in HIV patients is available in the current literature, this case is of significant interest.

Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity

OBJECTIVE

Treatment with indinavir/ritonavir (IDV/RTV) is very effective but hampered by frequent development of IDV-associated adverse events (mainly nephrotoxicity and skin changes). We tested whether dose reduction of IDV guided by therapeutic drug monitoring resulted in improved tolerability without compromising antiviral efficacy.

PATIENTS

HIV-infected patients with any IDV/RTV regimen who suffer from IDV-related adverse events were included. Viral load had to be adequately controlled for at least 2 months prior to inclusion. Dose reduction from 800 mg to 600 or 400 mg IDV b.i.d. followed a specified protocol. IDV-related toxicity and IDV plasma concentrations were monitored for 24 weeks. IDV concentrations were quantified with a validated high performance liquid chromatography method.

RESULTS

Twenty patients were included. Reasons for inclusion were: skin abnormalities 11, nephrotoxicity five, metabolic disturbances three, and hypertension one. IDV dose could be lowered to 400 mg b.i.d. in 13, to 600 mg b.i.d. in two patients. Five patients discontinued the treatment. Overall tolerability improved with respect to incidence and severity of adverse events. Median trough concentrations decreased from 1.02 mg/l (range 0.08-7.1) at baseline to 0.48 mg/l (0.11-1.4) after 24 weeks (p = 0.03) and remained above the critical threshold of 0.1 mg/l at any time after dose reduction. There was no change of CD4 cell counts or viral suppression. There were no significant changes in other laboratory parameters (creatinine, bilirubin, triglycerides, cholesterol, blood count, and urinalysis).

CONCLUSION

Dose reduction of IDV improved tolerability of IDV-containing highly active antiretroviral treatment (HAART). Sufficient IDV trough concentrations were maintained in all patients as was virologic control.

Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring

OBJECTIVE

To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients.

METHODS

HIV1-infected treatment naive patients were prospectively randomized to treatment with IDV 600 mg or 400 mg BID each in combination with RTV 100 mg BID. Boosted IDV was combined with 2 NRTI, and patients were followed for 48 weeks. IDV-trough levels and initially also peak levels (C2h) were performed to allow dose modification of IDV following a specified protocol.

RESULTS

14 patients were randomized (age 38 +/- 10.4 years; mean +/- SD; 3 female, 11 male). 8 were treated with 600 mg (group 1), 6 with 400 mg IDV BID (group 2). Efficacy of treatment was good: CD4-cell count increased from 198/microl (14-523; median, range) to 371/microl (214-927) after 48 weeks (p<0.01). All but one patient with adherence problems achieved a viral load below the limit of detection. At the beginning two patients had plasma levels below 0.1 mg/l, most likely due to adherence problems. However, in the course of the observation period all patients had adequate plasma levels. 3 patients in group 1 could further reduce their IDV dose to 400 mg BID due to high plasma (peak and trough) levels. Rate of discontinuation was high (1: 4 pat., 2: 2 pat.), but only one discontinuation was possibly associated with IDV (alopecia; group 2). There were no significant changes in laboratory parameters (bilirubin, triglycerides, cholesterol) or suspicious urine results. Incidence and severity of adverse events was lower than in previous studies.

CONCLUSION

Despite the low number of patients it seems reasonable to state, that boosted IDV may be used in significantly reduced dose. Efficacy seemed not to be altered, whereas tolerability was improved.

Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion

BACKGROUND

The immunological and clinical benefits of structured treatment interruptions (STIs) during primary HIV-1 infection remain largely unclear.

PATIENTS AND METHODS

Eight patients identified during primary HIV-1 infection were immediately treated with HAART and underwent subsequent STIs after reaching complete viral suppression of HIV-RNA in peripheral plasma. HAART was re-initiated if either HIV-1 RNA >5000 copies/ml, CD4-cells <200 cells/microl or symptomatic HIV-1 disease was observed.

RESULTS

After treatment discontinuation, four of eight patients were able to persistently control HIV-1 viremia below 5000 copies/ml until the last time point of follow-up (median 3 years). CD4-cell counts were within the interquartile range of untreated individuals compared to historical reference data from the MACS cohort. In the remaining study subjects persistent virological control was not reached despite repeated STIs. Moreover, compared to the MACS cohort repetitive virological failures during STIs appeared to induce an accelerated decline of CD4-cells.

CONCLUSION

Spontaneous HIV-1 control after treated primary HIV-1 infection was possible in four out of eight individuals, however, if STIs after treated primary infection ameliorate the overall HIV-1 disease progression remains unknown. In the absence of viral control, repetitive viral exposure during STIs might be associated with accelerated decline of CD4-cell counts.

Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results

BACKGROUND

Within this open-label, uncontrolled prospective trial we evaluated safety, efficacy and development of genotypic resistance under the new protease inhibitor lopinavir/ritonavir (LPV/r) in antiretroviral (ARV) HIV patients.

PATIENTS AND METHODS

58 patients with virological failure under their current ARV therapy were started on a LPV/r containing regimen. Median baseline HIV RNA and CD4 count were 4.6 log(10) cps/ml (range 2.1-6.4) and 128 x 10(6)/l (0-767), respectively. CD4 count, HIV RNA and metabolic parameters were assessed at weeks 0, 4, 8, 12, 16, 24, 32, 40, 48. Genotypic resistance testing was performed at baseline and again at weeks 12, 24 and 48 in the event of virological failure.

RESULTS

Until week 48, viral load (VL) decreased by a median of 1.9 log(10) cps/ml (-0.8-3.8). A VL below 80 cps/ml was found in 20/58 patients (34.5%) at week 48. In parallel, CD4 cells increased to a median of 332 x 10(6)/l (8-905). Nine patients discontinued study treatment. At 48 weeks, median triglyceride and cholesterol levels increased significantly. While the median number of overall protease mutations at baseline was four in all patients, it was six in patients virologically failing on LPV/r. The average number of mutations increased significantly to eight at week 48. Several mutations were detected considerably more often in the event of failure than in response to treatment, e. g. at amino acid positions 10, 24, 54, 71, 82, 84.

CONCLUSION

LPV/r is effective in heavily pretreated patients. Discontinuation due to adverse events is infrequent. No individual mutation can be associated with failure on LPV/r. However, a greater number of protease mutations at baseline is associated with poorer treatment outcome and several mutations seem to be related to treatment failure.

First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results

OBJECTIVES

To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2-3 nucleoside reverse transcriptase inhibitors (NRTI) in antiretroviral-naive patients.

METHODS

Within this open-label, uncontrolled multicentre trial, antiretroviral-naive patients (n = 57) with median baseline HIV-RNA of 308,000 copies/mL (range 170-3.01 million copies/mL) and median CD4 cell count of 50 cells/microL (range 0-853 cells/microL) were started on 2-3 NRTIs plus ritonavir/indinavir 100/800 mg twice daily. CD4 cell counts and HIV-RNA were determined at weeks 0, 4, 8, 12, 16, 20, 24 and 48. Statistical analysis was performed on treatment as well as intent-to-treat.

RESULTS

Viral load decreased by a median of 3.79 log10 copies/mL (range 2.0-4.60 log10 copies/mL) until week 48. At week 48, 23/57 (40%, intent-to-treat) patients showed a viral load </= 80 copies/mL. In parallel, median CD4 cell counts increased by a median of 149 cells/microL (range -60-420 cells/microL). Median triglycerides and cholesterol increased from baseline 160 mg/dL (range 33-364 mg/dL) to 218 mg/dL (range 110-527 mg/dL) at week 48 and from 166 mg/dL (range 63-262 mg/dL) to 233 mg/dL (range 95-359 mg/dL), respectively. Twenty-seven of fifty-seven patients (47%) discontinued study medication, 19 (33%) due to nephrolithiasis. Two patients changed their antiretroviral regimen after failing virologically.

CONCLUSION

Ritonavir/indinavir 100/800 mg twice daily appears to be effective up to 48 weeks despite high baseline viraemia and low CD4 cell count in antiretroviral-naive patients. However, discontinuation due to adverse events, especially nephrotoxicity, is frequent and limits treatment duration. Therefore, extra hydration appears inevitable with this combination.

[Association of primary sclerosing cholangitis and sarcoidosis]

BACKGROUND

Primary sclerosing cholangitis and sarcoidosis are rarely associated diseases.

CASE REPORT

We report the case of an 42-year-old woman with primary sclerosing cholangitis confirmed by endoscopic cholangiography, biopsy of the liver and serum neutrophil cytoplasmatic antibodies. Furthermore radiological and histological signs of pulmonary and hepatic manifestation of sarcoidosis were observed, besides there were alopecia areata and choledocholithiasis.

CONCLUSION

The present case report gives a brief survey of the literature, reflects the theories to unknown etiology and reports actual aspects of diagnosis and therapy of both diseases.

Cutaneous manifestations in inflammatory bowel disease

Numerous extraintestinal manifestations in various organ systems have been reported to be associated with inflammatory bowel disease (IBD). Aim of the present paper was to evaluate the frequency of cutaneous manifestations in Crohn's disease (CD) and ulcerative colitis (UC) with respect to their location, the activity and location of the underlying disease, the treatment options and the time to remission.

METHODS

The medical records of 1043 inpatients with CD and UC were screened retrospectively for extraintestinal symptoms with special regard to cutaneous manifestations.

RESULTS

The prevalence of cutaneous manifestations in IBD was 22/1043 (2.1%; 18 women, 4 men; age: 31.41 +/- 9.9 [21-51] yrs.). In 15/22 patients (68.2%) the cutaneous manifestations were associated with CD, in 7/22 patients (31.8%) UC was confirmed. In 6/22 patients (27.3%) pyoderma gangrenosum (PG) was diagnosed, in 16/22 patients (72.7%) erythema nodosum (EN). EN and PG predominately occurred at the lower legs: in 68.1% the tibia was the main affection site. Other locations like breast or anus were rare. In 16/22 patients (72.7%) an acute phase of the underlying disease was evident, in 6/22 patients (27.3%) CD or UC were in remission. In patients with CD a colonic involvement was found in 86.7%. Arthritis was the most frequent coexisting extraintestinal manifestation in CD (53.3%) and UC (28.8%). Drug treatment was performed with high doses of glucocorticoids and salicylates. The time to remission in patients with EN was significantly shorter as compared to PG (5.3 +/- 1.8 vs. 19.6 +/- 14.2 weeks; p < 0.001). In 5/22 patients (22.7%) cutaneous manifestations reoccurred after a symptom-free interval. All efflorescenses reoccurred during an active phase of the underlying disease at the same manifestation site as the initial presentation.

CONCLUSION

In this series the prevalence of cutaneous manifestations in IBD was 22/1043 (2.1%). EN and PG were more frequent in women with IBD, in CD, and during the acute phases of the underlying disease. EN and PG predominately affect the lower legs. Cutaneous manifestations respond well to an acute phase therapy of the underlying disease. The time to remission was significantly shorter in EN as compared to PG. However, relapses have to be considered in a relevant subgroup of patients.

Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease

BACKGROUND/AIMS

Vascular endothelial growth factor (VEGF), a potent angiogenic, permeability-enhancing cytokine plays an important role in tissue repair and chronic inflammatory disorders. Peripheral blood mononuclear cells (PBMCs) and the inflamed mucosa have been demonstrated to be main sources of the recently described circulating VEGF in patients with inflammatory bowel disease (IBD). There is no current information about the influence of immunoregulatory cytokines on VEGF in IBD. The present study examines the effect of interleukin-4 on the increased VEGF production of PBMCs in patients with IBD.

METHODOLOGY

Unstimulated PBMCs from 17 patients with Crohn's disease, 16 patients with ulcerative colitis and 8 healthy controls were cultured with or without IL-4. VEGF production was measured in the supernatant using an enzyme-linked immunosorbent assay.

RESULTS

IL-4 led to a significant reduction of the VEGF production by PBMCs of both active Crohn's disease patients (471.7 +/- 377.5 pg/mL vs. 208.2 +/- 123.2 pg/mL, P = 0.018, n = 7) and active ulcerative colitis patients (177.1 +/- 79.4 pg/mL vs. 87.4 +/- 77.2 pg/mL, P = 0.008, n = 9). IL-4 inhibited significantly the VEGF production by PBMCs of patients with inactive Crohn's disease (179.2 +/- 133.9 pg/mL vs. 87.7 +/- 56.6 pg/mL, P = 0.005, n = 10). There was no significant difference of VEGF release by PBMCs cultured with IL-4 in patients with active Crohn's disease or active ulcerative colitis compared with PBMCs cultured without IL-4 in patients with inactive disease and healthy controls (112.6 +/- 41.9 pg/mL, n = 8).

CONCLUSIONS

IL-4 has been shown to reduce the increased VEGF production of PBMCs in patients with IBD to normal levels. The known defective immunosuppressive effect of IL-4 in IBD may contribute to the pathogenic cascade leading to inflammation by VEGF mediated mechanisms.

Polymyositis of the skeletal muscles as an extraintestinal complication in quiescent ulcerative colitis

Myositis of the skeletal muscle is a rare complication of inflammatory bowel disease. We report about a 33-year-old woman with quiescent ulcerative colitis known since 1995. She had suffered from recurring fever and pain in the thighs for about 4 weeks. Electromyography of quadriceps and deltoid muscles revealed myopathic changes. Diagnosis of polymyositis was confirmed by magnetic resonance imaging indicating edematous changes in the distal extremity muscles. The symptoms rapidly responded to high doses of steroids. Review of the literature indicates only a few cases describing an association of ulcerative colitis and myositis, most of them during acute exacerbations of the disease. In contrast, the present patient was in remission. Diagnosis of myositis should be considered in inflammatory bowel disease patients complaining of myalgia or muscular weakness. Magnetic resonance imaging may show specific features and can be used in addition to laboratory investigations and muscle biopsy for diagnosis of polymyositis.

Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease

BACKGROUND/AIMS

Vascular endothelial growth factor (VEGF) is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Recent studies have shown significantly increased VEGF serum levels in patients with active Crohn's disease and ulcerative colitis. The origin of the circulating VEGF is not yet completely described. The present investigation examines the VEGF production of colonic mucosa in consideration of mucosal disease activity in patients with inflammatory bowel disease.

METHODOLOGY

Fifteen patients with inflammatory bowel disease were studied, 9 patients with Crohn's disease and 6 patients with ulcerative colitis. Biopsies were taken from endoscopically inflamed and non-inflamed colonic mucosa. Therefore, an analysis of the spontaneous VEGF production of cultured biopsies without stimulus and of the histological grade of inflammation scored on a scale of 0-3 (normal mucosa--severe chronic colitis) were performed. Eight patients with irritable bowel syndrome served as controls. VEGF levels in the supernatant of cultured mucosal biopsies were measured using an enzyme linked immunosorbent assay.

RESULTS

VEGF production is expressed as pg/mg wet weight of the biopsies. Inflamed mucosa of patients with active ulcerative colitis (16.27 +/- 10.39, p = 0.003, n = 6) and active Crohn's disease (9.88 +/- 5.98, p < 0.012, n = 9) showed a significantly higher spontaneous production of VEGF by colonic mucosa than normal mucosa of controls (3.16 +/- 1.63, n = 8). In addition, there was an increased unstimulated VEGF production by cultured inflamed mucosa of patients with Crohn's disease compared with non-inflamed mucosa (3.88 +/- 3.66, p < 0.015, n = 9). In both Crohn's disease and ulcerative colitis, there was no significant difference between VEGF production by non-inflamed mucosa and normal mucosa of controls.

CONCLUSIONS

The present study identifies the intestinal mucosa as one of the origins of the elevated VEGF serum levels in patients with active inflammatory bowel disease and verifies the findings of recent studies about the importance of VEGF in Crohn's disease and ulcerative colitis.

[Atelectasis - bronchoscopy and unilateral ventilation]

Atelectasis in the postsurgical patient or patients on artificial ventilation problems is a frequently occurring complication. Bronchoscopy, local secretion removal by suction, lavage and vigorous positive pressure ventilation in many cases fail to re-expand the collapsed lung. Intubation after bronchoscopy by a double lumen tube permits systematic overinflation of the collapsed lung whereas the other lung is open to atmospheric pressure. In this manner the opening pressure of the collapsed lung can be overcome without overdistension of the other lung. The result is a marked improvement of oxygenation by reducing the venous admixture in lung.

[Lung function after thoracic trauma. A contribution to the assessment of late functional lesions (author's transl)]

Respiratory function was investigated in 32 patients not later then 5 years after thoracic trauma. Forced expiration curves (volume/time and flow/volume mode) and nitrogen washout methods (single breath, multiple breath) were used including blood gas analyzes and thorax-X-rays. The typical effect of chest injury is mild to moderate restriction, which was found in 72% of the patients. Usually all volumes (FVC, FRC, TC) are reduced. 5 patients had slight to moderate obstruction, which we do not consider to be immediate consequence of trauma. 12 patients had signs of ventilatory maldistribution, which can be explained by reduced FRC in more or less all cases and obstruction in the above mentioned 5 patients. Observation of two cases leads us to conclude that chest injury may initiate development of chronic respiratory disease and that such a disease may be aggravated by thoracic injury. Motivation, young age, quality of rehabilitation, dorsal location of fractured ribs may help to improve the pulmonary status of the patient, existing or developing chronic lung disease, smoking, old age, lateral localisation of fractured ribs with dislocation will hinder improvement.

[Systolic time intervals during increasing left ventricular filling pressure following extracorporeal circulation. A comparative impedance-cardiographical study (author's transl)]

In 26 patients invasively measured haemodynamic parameters and impedance cardiographically determined systolic time intervals have been compared after open heart surgery with cardio-pulmonary bypass (aortic valve replacement, AVR (n = 7); mitral valve replacement, MVR (n = 7); aorto-coronary bypass, ACB (n = 10)). In both the AVR and ACB group an increase of left atrial pressure resulted in 1) a significant increase of left ventricular stroke work index (LVSWI), 2) a significant decrease of the relation of the pre-ejection period to left ventricular ejection time (PEP/LVET), and 3) a significant increase of cardiac output (thermodilution technique and impedance cardiography), whereas no significant alterations were found in the MVR group. Furthermore cardiac output determination using both the direct thermodilution technique and the indirect impedance method revealed a close correlation (n = 63, range cardiac output 1.5-12.51/min, r = 0.852). These data clearly demonstrate the utility of the non invasive impedance cardiography method compared with invasive methods with respect to measurement of cardiac and haemodynamic parameters, even in critical situations.

[Resuspension of erythrocyte concentrates: clinical examinations with human albumin and oxypolygelatine]

The acid-base status of packed red cells and the influence of resuspension with human albumin, oxypolygelatine (Gelifundol), Human-serum and physiological saline were examined. It was found that the severe metabolic acidosis of packed red cells increased only slightly with storage time, while the resuspension exerted divergent effects: Human albumin and physiological saline increased the metabolic acidosis slightly, but significant. Humanserum and oxypolygelatine diminished it because of their bicarbonate content. The clinical significance especially in massive transfusion is discussed.

[The influence of LAP and cardiac output on the pulmonary gas exchange. Intraoperative studies in cardio-surgical patients (author's transl)]

In 21 patients haemodynamic parameters and pulmonary gas exchange were investigated after open heart surgery with cardio-pulmonary bypass (aortic valve replacement, AVR (n = 8); mitral valve replacement, MVR (n = 6); aorto coronary bypass; ACB (n = 7). For describing gas exchange function of the lung the O2-CO2 diagram was used. Stepwise increase of left atrial pressure (LAP) was followed by increasing cardiac output (CO) only in the AVR and ACB groups, whereas in the MVR group CO did not increase. Rising venous admixture (Qs/Qt) under these circumstances was related to CO only in the AVR and ACB groups. In the MVR group Qs/Qt did not change. Qs/Qt is related to low VA/Q areas in the lung. Increased CO leads to rising Qs/Qt from these low VA/Q-areas.

[Optimal left ventricular filling pressure after cardiopulmonary bypass (author's transl)]

To determine the optimal left ventricular filling pressure (LAP) after cardiopulmonary bypass (CPB) left ventricular function curves were constructed in ten patients with coronary heart disease, seven with aortic stenosis and normal left ventricular filling pressures (NLVFP), eight with aortic stenosis and pathologic elevated left ventricular filling pressure (ELVFP), and nine with mitral valve disease, cardiac index = CI, stroke index = SVI, left ventricular stroke work index = LVSWI were plotted against left atrial pressure = LAP and correlated with myocardial lactate extraction. After CPB, CI and LVSWI increased 52 to 53% and 50 to 80%, respectively, in the patients with NLVFP. In the patients with preoperatively ELVFP SVI did not increase significantly with increasing LAP, resulting in no augmentation of CI and LVSWI. Total systemic resistance increased in these patients, and myocardial lactate metabolism shifted to production in the patients with severe aortic stenosis. Thus, the results show that SVI, CI and LVSWI cannot be augmented by increasing LAP above 15 mm Hg if preoperative left ventricular function is already impaired. Elevation of LAP above 20 mm Hg can induce myocardial ischemia and cause low cardiac output with increased peripheral vascular resistance.

[The oxygen dissociation curve for the differentiation of peripheral anoxia (author's transl)]

By using a desk top calculator and a four-colour X-Y-plotter the standard and actual oxygen dissociation curves can easily be visualized. The pO2.50 and arteriovenous oxygen difference give information about the peripheral oxygen supply. Different types of peripheral anoxia can readily be evaluated by this graphical representation of the measured and derived data.

The colorimetric determination of HbA1c in normal and diabetic subjects

The parameters which influence the determination of the major glycosylated haemoglobin fraction (HbA1c) with the thiobarbituric acid (TBA) method are described. Conditions for an optimal determination method are given. The correlation with the fast haemoglobin determination by column chromatography is greater than 0.9. The influence of storage on blood, washed erythrocytes and haemolysate in respect to HbA1c values obtained with the method described, was also investigated. Normal and pathological values from 78 patients correlate well with the fasting blood sugar levels (r greater than 0.9).

[Direct measurement of blood pressure and pulse frequency by the blood pressure pulse monitor "Benjamin" (author's transl)]

A portable, battery powered blood pressure-pulse monitor is described. This device is suitable for direct monitoring of blood pressure and pulse frequency during operation, in the postoperative period as during inner clinical transport or aviation transport.

[Material changes of plastic syringes (author's transl)]

During storage of syringes changes can develop in the material possibly depending on surrounding conditions. This can lead to precipitation of oleic acid amide into the lumen of the syringe. This material floats in corpuscular form on the injection fluid.

[Mini-photometer and mini-centrifuge for determination of Hb and Hk (author's transl)]

A Mini-Photometer and a Mini-Centrifuge for determination of Hb and Hk are described. These devices are simple to use, compact in size and sufficiently accurate for clinical use in a variety of circumstances.

Enlarged acid-base and blood gas calculations by electronical data computing in the blood gas laboratory

A rapid anaysis of parameters of the acid-base equilibrium and blood gases during open heart surgery and emergency therapy is absolutely necessary. Computing of the several parameters of the acid-base status by slide rules or nomograms is time consuming and can be shortened by computer applications. The central blood gas laboratory consists of a blood gas analyzer for PO2, PCO2 and pH, an electronic desktop calculator, a four color X-Y-plotter and two data lines to the cardiac surgery unit and to the intensive care unit. The time needed for computing and feedback of the parameters could be decreased to one quarter. In addition to numerical data printout, a graphical representation of the several parameters is possible on a X-Y-plotter and includes the Rahn-Fenn-O2-CO2-Diagram with venous admixture, ventilation perfusion ratio, alveolar dead space ventilation and the standard and actual oxygen dissociation curve as well as the pH/HCO3- Acid-Base nomogram. Furthermore, a computer diagnosis of the actual disturbances can be plotted.

[Necessity to control endexpiratory CO2-concentration during laparoscopic sterilisation under general anaesthesia with controlled ventilation (author's transl)]

During laparoscopy and intraabdominal insufflation of CO2 cardio-respiratory accidents following increased PaCO2 are possible. The continuous measurement of endexpiratory CO2-concentration by infrared absorption spectrometry is a simple method for controlling the level of ventilation. Respiratory acidosis under controlled artificial ventilation during laparoscopy can thus be avoided.

[The role of ventilatory disturbances in the late postoperative hypoxaemia after upper abdominal surgery. A contribution to the risk of upper abdominal surgery in patients with respiratory damage (author's transl)]

The purpose of our investigations was to evaluate the influence of disturbed inspiratory gas distribution on postoperative hypoxemia in patients with abnormal lung function undergoing upper abdominal surgery. The lung function analyzer Hewlett-Packard 47402 A was used (Volume-time and flow-volume curves of forced expiration, single and multiple breath nitrogen washout tests with indices of ventilatory gas distribution). It was demonstrated that postoperative hypoxaemia in the undamaged lung is almost exclusively the result of augmented true right to left shunt. In patients with abnormal lung function the cause of postoperative hypoxaemia is, for the most part, an increase of disturbances of ventilatory gas distribution. These changes in the postoperative period can be explained by a reduction of FRC, that follows from changing of position (sitting-lying) and from pain. In patients with borderline lung function this reduction of FRC postoperatively may limit surgical treatment. The management of pain is of great importance in these patients. Continuous epidural anaesthesia certainly produces the best results in this respect.

[Data processing in the blood gas laboratory (author's transl)]

A computer-assisted system for the calculation of derived blood-gas and acid-base parameters, consisting of an analysator (AVL 937) desk calculator (HP 9825A) and external printer (HP 5150A) is described. For the calculation of the derived parameters corrections were made for patient temperature, plasma protein, reduced haemoglobin and CO2-carbamino haemoglobin. The time needed for calculating and feed back was shortened.

[A new CO2 analyzer for monitoring of artificial ventilation (author's transl)]

A new CO2-Analyzer for continuous measurement of CO2 content during artificial respiration is described. Based on infra red absorption, this device may be used for measuring the carbon dioxide content of expiration in anaesthesia and intensive care. Carbon dioxide infrared absorption is affected by nitrous oxide. This side effect can be compensated by a single switch, if the sample contans N2O.

[Acute posttraumatic renal failure following therapy with antibiotics and beta-aescin (author's transl)]

A case of acute renal insufficiency after therapy with gentamycin and beta-Aescin is reported. The role of these two agents in the causation of the acute renal failure is discussed. Renal function was restored using the REDY-Hemodialization System.

[Ventilation distribution disorders. Evaluation based on nitrogen elimination curves of the lung and on an inspiratory gas-distribution index derived from it]

An uneven distribution of the inspiratory gas volume to the alveolar volume leads to disturbances of the ventilation/perfusion ratio VA/Q with resulting arterial hypoxemia. These ventilatory disturbances can be verified by nitrogen-washout-curves and an inspiratory gas distribution index derived from those curves. Preoperative diagnostic and the control of respiratory diseases during intensive therapy are possible without technical difficulties.

[Closing volume and ventilatory distribution disturbances (author's transl)]

Ventilatory disturbances are induced by airway closure associated with an increase of the venous admixture from alveoli with a low ventilation-perfusion-ratio. Closing volume was measured by single breath nitrogen washout curves and correlated with ventilatory disturbances derived from multiple breath nitrogen washout curves and an inspiratory gas distribution index (IDI). There was present a close correlation between the closing volume in relation to the functional residual capacity and the IDI. With rising closing volume in relation to functional residual capacity a deterioration of the inspiratory gas distribution with increasing venous admixture was observed.

[Disturbances of ventilatory distribution as a cause of postoperative hypoxemia after cardio-thoracic surgery (author's transl)]

In a group of 21 patients with thoracotomy the lung function was investigated pre-and postoperatively with particular consideration to N2-clearance. From the N2-clearance an Inspiratory Gas Distribution Index (IDI) is derived. This Index allows in combination with blood gas analysis an interpretation of ventilatory disturbances in the lung.

[Studies on reducing the crude protein content of feeds fed to chicks and young hens (laying stock)]

2 rearing trials were carried out on a total of 8550 hybrid chicks (White Leghorn) to investigate in which way food mixtures containing reduced levels of crude protein (supplemented or unsupplemented with amino acids) might influence the growth of chicks and young hens. Decreases from 21.5% to 16.5% in the crude protein content of chicken feed and from 15% to 13% in feeds feed to young hens (greater than 8 weeks of life) did not reduce the live weight of birds at the end of the rearing period to any appreciable extent. No clearly defined differences were found to exist between the different types of feed tested concerning the amount of food and energy consumed per unit of weight gain and the mortality rate among the birds; it was shown, however, that the demand for crude protein per unit of weight gain was clearly reduced in birds reared at the lower crude protein level. For young hens receiving the diet poorer in protein the date when the birds began laying was slightly delayed. Otherwise, no statistically significant differences were found to exist between the young birds fed varying levels of crude protein, concerning the age at 50% laying performance and other parameters that are characteristic of the entire laying period (laying performance, weight of individual eggs, food consumption, mortality, fertilization of hatching eggs, hatchability of eggs). It appears that the feeding of a reduced protein diet to chicks and young hens (laying stock) did not have any detrimental effect on the growth and later laying performance of the birds. Apart from the fact that the demand for protein feeds is considerably reduced during the rearing period the costs of feeding per bird can also be cut down.

[Gas exchange and pulmonary mechanics under anaesthesia and artificial ventilation (author's transl)]

During general anaesthesia with controlled ventilation and normocapnia the A-a DO2 and pulmonary shunt were investigated in a group of 7 patients undergoing a parotidectomy or laryngectomy. In a second group of 21 patients the behaviour of the total, lung- and thorax compliance was investigated. Within the first 1 1/2 hours after induction of anesthesia the A-a DO2 and shunt increased. During the time the thorax compliance did not change, whereas the total and lung compliance decreased significantly. After 1 1/2 hours no further change occured.